ARS-1620

News alerts, weekly reports and conference planners

Company:

Araxes Pharma, J&J, Kura Oncology

Drug class:

KRAS G12C inhibitor

Related drugs:

KRAS G12C	Lung Adenocarcinoma	KRAS G12C	Lung Adenocarcinoma	everolimus + ARS-1620 Sensitive: D – Preclinical everolimus + ARS-1620 Sensitive : D	everolimus + ARS-1620 Sensitive: D – Preclinical everolimus + ARS-1620 Sensitive : D
KRAS G12C	Lung Non-Small Cell Squamous Cancer	KRAS G12C	Lung Non-Small Cell Squamous Cancer	everolimus + ARS-1620 Sensitive: D – Preclinical everolimus + ARS-1620 Sensitive : D	everolimus + ARS-1620 Sensitive: D – Preclinical everolimus + ARS-1620 Sensitive : D

Associations
(2)